Who We Are
Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Our Late- Stage Clinical Programs
Kamada is focusing on the development of biopharmaceutical products. These include its intravenous (IV) and inhaled (IH) Alpha-1 Antitrypsin (AAT) protein.
Kamada is currently in advanced discussions with the U.S. FDA in order to conduct a Phase 3 pivotal study of inhaled AAT for the treatment of Alpha-1 Antitrypsin Deficiency. Kamada is also dedicated to the research of AAT and its potential therapeutic characteristics for novel indications. The company has a late-stage AAT product candidates in development, including a designated intravenous formulations for GVHD, Type-1 Diabetes, and Lung Transplantation.
